LFCR Lifecore Biomedical, Inc. Total Debt to Capital
Lifecore Biomedical (LFCR) generates revenue by creating complex hyaluronic acid compounds, which enables the company to maintain significant pricing power. The business relies on stable chemical raw material supplies managed through a predictive control system. This chart of current share prices reflects the separate_debt_total_eq metric at 9.19. Additionally, Lifecore Biomedical (LFCR) is integrating AI and robotics into its sterile manufacturing to reduce manual labor and eliminate defects during syringe filling.
Analytical breakdowns and data insights for company Lifecore Biomedical, Inc. (LFCR)
Lifecore Biomedical (LFCR) maintains a stable roster of biomaterials experts, which minimizes operational risks during scaling. By analyzing the business's leverage ratio, an investor assesses the proportion of borrowed funds relative to equity. This metric determines the company's degree of financial autonomy and its resilience to changes in Fed rates. The price action filters out market noise, revealing the actual debt load. The consensus confirms that moderate leverage supports growth without the threat of bankruptcy.